SummaryThe bronchodilator and cardiac effects produced by aerosols of 0G5% salbutamol and 0(5% and 1% rimiterol administered for three minutes in 40% oxygen by intermittent positivepressure ventilation (I.P.P.V.) were compared in 15 asthmatic patients. Salbutamol and both the concentrations of rimiterol were equipotent in peak bronchodilator effect, but salbutamol had a significantly longer duration of bronchodilator action. There was significantly less increase in heart rate after rimiterol than after salbutamoL Aerosols of 0-5% rimiterol, 0 5% salbutamol, and saline were administered by I.P.P.V. to 10 normal volunteers. There was no difference between the mean heart rates after 0 5% rimiterol and saline but a highly significant increase in mean heart rate was observed after 05% salbutamol. It was concluded that 0(5% rimiterol was an effective short-acting bronchodilator drug with little or no cardiac beta1-adrenergic activity when administered for three minutes by I.P.P.V. in 40% oxygen.
SummarySalmefamol is a new sympathomimetic drug with predominantly P2 actions. In a double-blind trial in a group of twenty-four patients with airway obstruction, we have compared the effect of 100 tig of salmefamol given by metered aerosol with that of a placebo aerosol. In the same patients we have also compared the aerosols with subcutaneous adrenaline and subcutaneous atropine, the sequence of treatments being determined by a latin square design.At all times salmefamol had a significantly greater bronchodilator effect than the placebo. Although the effects of atropine and adrenaline were greater at the earlier times of measurement, that of salmefamol was greater at 4 hr.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.